ECTRIMS 2025: NMSS funding, support drives progress in care
Bruce Bebo, executive vice president of research at the National MS Society, says NMSS investments are helping advance MS research and care.| Multiple Sclerosis News Today
Bruce Bebo, executive vice president of research at the National MS Society, says NMSS investments are helping advance MS research and care.| Multiple Sclerosis News Today
Lindsey Shapiro is a science writer for Multiple Sclerosis News Today with a PhD in neuroscience. She covers the latest news and information on a variety of multiple sclerosis topics.| Multiple Sclerosis News Today
A team of scientists analyzed data from over a dozen studies involving more than 900 people with MS to research iron rim lesions.| Multiple Sclerosis News Today
Exercise effectively eases fatigue and improves muscular fitness in MS patients, but the best type differs for each outcome, per an analysis.| Multiple Sclerosis News Today
Transcranial direct current stimulation (tDCS) didn't outperform a sham treatment in easing fatigue in adults with multiple sclerosis.| Multiple Sclerosis News Today
Certain immune cells in MS show abnormalities in activity and signs of reactions against the Epstein-Barr virus, a study says.| Multiple Sclerosis News Today
In MS, slowly expanding lesions were linked to more myelin loss in brain regions of damage and in normal-appearing brain tissue, per a study.| Multiple Sclerosis News Today
Columnist Ben Hofmeister offers insight into his strategy of learning about MS care by using knowledge he already has.| Multiple Sclerosis News Today
Marisa Wexler is a senior science writer for Multiple Sclerosis News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of multiple sclerosis topics.| Multiple Sclerosis News Today
Migraines affect around 24% of people with MS, and are about two times more likely to occur in these patients than in healthy individuals.| Multiple Sclerosis News Today
There are several approved MS medications, from disease-modifying therapies to symptomatic treatments. Learn more about them here.| Multiple Sclerosis News Today
Fampyra (fampridine), which is approved to boost walking ability in adults with MS, may help people with poor working memory, a study says.| Multiple Sclerosis News Today
Abata Therapeutics has chosen its first treatment candidate for development: the T-cell therapy ABA-101 for certain forms of progressive MS.| Multiple Sclerosis News Today
Fatigue was shown to be a significant predictor of worse health-related quality of life in adults with relapsing-remitting multiple sclerosis.| Multiple Sclerosis News Today
Patricia Inacio is a science writer for Multiple Sclerosis News Today with a PhD in cell biology. She covers the latest news and information on a variety of multiple sclerosis topics.| Multiple Sclerosis News Today
Columnist Desiree Lama shares how a diagnosis of MS both halted her from scholastic pursuits and shifted her in a new direction.| Multiple Sclerosis News Today
Support and companionship are just a few benefits of having a cat, says columnist Desiree Lama, who writes about her furry friend, Lucky.| Multiple Sclerosis News Today
Columnist Susan Payrovi discovers how her body prefers to follow natural circadian rhythms, or biological clocks.| Multiple Sclerosis News Today
Learning to say no and prioritize her health has been crucial for columnist Desiree Lama, who lives with relapsing-remitting MS.| Multiple Sclerosis News Today
Category archive page for News.| Multiple Sclerosis News Today
In her columns debut, Desiree Lama shares the story of how vision loss and optic neuritis led to her multiple sclerosis diagnosis in 2016.| Multiple Sclerosis News Today
Spending time outdoors helps columnist Susan Payrovi wake up her body systems and manage her multiple sclerosis symptoms.| Multiple Sclerosis News Today
After a year, patients given CNM-Au8 had improvements in vision and data suggested the therapy improved the health of brain nerve fibers.| Multiple Sclerosis News Today
Most nonactive SPMS patients who took foralumab nasal spray for at least six months saw a decrease in microglial activity in their brains.| Multiple Sclerosis News Today
